Join the EASL Educational Committee!
The EASL Educational Committee provides scientific expertise and support to the EASL Governing Board and EASL office, in the development and monitoring of a high-quality portfolio of educational offerings in support of…
European Medicines Association (EMA) statement on Obeticholic acid for the treatment of primary biliary cholangitis (PBC) European Association for the Study of the Liver (EASL) perspective
The EMA human medicines committee (CHMP) has recently issued a statement on Obeticholic acid for the treatment of Primary Biliary Cholangitis (PBC). The CHMP recommended to the European Commission that the market…
First Patient Enrolled in Phase II Clinical Trial of DECISION’s COMBAT Trial
• First patient enrolled at Hôpital Beaujon, Clichy, France • The COMBAT Trial is a multicenter, randomized, open-label, Phase II clinical trial in patients with decompensated cirrhosis Barcelona, Spain, 9th July 2024…
EASL announces JHEP Reports’ Impact Factor of 9.5 for 2023
The European Association for the Study of the Liver (EASL)is delighted to announce that JHEP Reports, its Open Access publication, achieved an impressive impact factor of 9.5 in the 2024 release of…
EASL announces Journal of Hepatology’s exceptional Impact Factor of 26.8 for 2023
The European Association for the Study of the Liver (EASL) is proud to announce that the Journal of Hepatology, its flagship publication, achieved an impact factor of 26.8 in the 2024 release…
New Editor-in-Chief for EASL’s Journal of Hepatology: Vlad Ratziu
The European Association for the Study of the Liver (EASL) is proud to announce the appointment of Prof. Vlad Ratziu as the new Editor-in-Chief of the Journal of Hepatology, the premier publication…
Launching the EASL Guidelines App!
Introducing the EASL Guidelines App – your indispensable mobile companion for accessing comprehensive and up-to-date clinical practice guidelines in hepatology. Developed by EASL, the European Association for the Study of the Liver,…